The tetravalent BsAb (BC133) was more potent than the bivalent heterodimeric IgG platform (heterodimer) against human AML cells in vitro. TDCC in the presence of tetravalent BC133 vs bivalent heterodimer against CD33⁺ human AML cell lines was assessed by a 4-hour chromium release assay.